Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FibroGen names new vice president of clinical development
Dr Yu was most recently vice president of clinical research at Anesiva. Prior to Anesiva, Dr Yu was director of clinical development, at Alza, a subsidiary of Johnson
Dr Yu was most recently vice president of clinical research at Anesiva. Prior to Anesiva, Dr Yu was director of clinical development, at Alza, a subsidiary of Johnson
MEDI-563, which was generated using BioWa’s Potelligent technology platform, has previously been investigated in a Phase I open-label dose-escalating study to evaluate the safety and tolerability of a
According to the company, this innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath Pap test slides to detect evidence
The multi-national study has enrolled more than 330 patients and is designed to assess the efficacy and safety of bevasiranib administered every eight or 12 weeks in preventing
Prior to NovaRx, Dr Russell was the president and CEO of Kalos Therapeutics, a biotechnology company focused on the development of cancer therapies. Before Kalos, Dr Russell served
Pursuant to the terms of the contract, the Provincial Government of the Western Cape (PGWC) will implement the new Enterprise Edition of the JAC Pharmacy Management system in
Eczacibasi Ilac Pazarlama (EIP) has agreed to obtain the necessary regulatory approvals for the territory and to pay Vical upfront and milestone payments plus a specified transfer price
The trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in patients with solid tumors, including non-small cell lung cancer and prostate carcinoma. Merck is
AEterna Zentaris has received $52.5 million from Cowen Healthcare Royalty Partners (CHRP) at closing, less certain transaction costs. Under the terms of the agreement with CHRP, AEterna Zentaris
Mr Ford has over 20 years of experience at both biotechnology as well as major pharmaceutical companies. Mr Ford was most recently vice president of business development at